Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (1) : 80-85     DOI: 10.1007/s11684-011-0115-0
Successful kidney transplantation in highly sensitized patients
Weijie ZHANG, Dong CHEN, Zhishui CHEN, Fanjun ZENG, Changsheng MING, Zhengbin LIN, Ping ZHOU, Gang CHEN, Xiaoping CHEN()
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Health, Wuhan 430030, China
Download: PDF(121 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Highly sensitized patients experience an increased number of rejection episodes and have poorer graft survival rates; hence, sensitization is a significant barrier to both access to and the success of organ transplantation. This study reports our experience in kidney transplantation in highly sensitized patients. Fourteen patients with sensitization or high levels of panel-reactive antibodies (PRA) were studied. All patients were desensitized with pre-transplant intravenous immunoglobulin (IVIG)/plasmapheresis (PP) with or without rituximab and thymoglobulin induction therapy, combined with a Prograf/MMF/Pred immunosuppressive regimen. Of 14 patients, 10 showed good graft functions without acute rejection (AR) episodes. Acute cellular rejection in two patients was reversed by methylprednisolone. Two patients underwent antibody-mediated rejection; one was treated with PP/IVIG successfully, whereas the other lost graft functions due to the de novo production of donor-specific antibodies (DSA). Graft functions were stable, and there were no AR episodes in other patients. Conclusively, desensitization using PP/IVIG with or without rituximab increases the likelihood of successful live-donor kidney transplantation in sensitized recipients.

Keywords Kidney transplantation      desensitization     
Corresponding Authors: CHEN Xiaoping,   
Issue Date: 05 March 2011
URL:     OR
Age (mean±SD)43.6±7.4
Sex (M:F)8∶6
Etiology of renal failureChronic glomerulonephritis
Polycystic kidney disease
No. of Tx (1st:2nd)4∶10
HLA MM No. (mean±SD)2.7±1.4
Previous transfusion9
Previous transplantation10
Previous pregnancy4
Tab.1  Patient and transplant-related characteristics
Fig.1  Changes in PRA levels before and after desensitization treatment. All patients showed a decrease in PRA levels. The mean decreases in PRA class I and class II levels were 43.6% and 38.5% respectively.
Fig.2  Changes in mean serum creatinine concentration and GFR levels in functioning allografts. Serum creatinine and GFR were 886±114.1μmol/L and 33.2±1.6 mL/min ( = 14) at 1st day post-transplantation respectively, and serum creatinine and GRF were 101±19μmol/L and 45.5±1.8 mL/min ( = 13) at 12 months post-transplantation respectively.
1 Vasilescu E R, Ho E K, Colovai A I, Vlad G, Foca-Rodi A, Markowitz G S, D’Agati V, Hardy M A, Ratner L E, Suciu-Foca N. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol , 2006, 67(8): 597-604
doi: 10.1016/j.humimm.2006.04.012 pmid:16916655
2 Gebel H M, Moussa O, Eckels D D, Bray R A. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol , 2009, 70(8): 610-617
doi: 10.1016/j.humimm.2009.04.012 pmid:19375473
3 Flores-Gama F, Mondragón-Ramírez G A, Bochicchio-Riccardelli T. Desensitization and renal transplant: plasmapheresis/IVIG standard dose in patients with high immunological risk. Cir Cir , 2009, 77(5): 369-374
4 Varma P P, Hooda A K, Kumar A, Singh L. Highly successful and low-cost desensitization regime for sensitized living donor renal transplant recipients. Ren Fail , 2009, 31(7): 533-537
doi: 10.1080/08860220903001861 pmid:19839846
5 Kim S M, Lee C, Lee J P, Kim E M, Ha J, Kim S J, Park M H, Ahn C, Kim Y S. Kidney transplantation in sensitized recipients; a single center experience. J Korean Med Sci , 2009, 24 (Suppl): S143-S147
doi: 10.3346/jkms.2009.24.S1.S143 pmid:19194544
6 Faenza A, Fuga G, Bertelli R, Scolari M P, Buscaroli A, Stefoni S. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible? Transplant Proc , 2008, 40(6): 1833-1838
doi: 10.1016/j.transproceed.2008.05.078 pmid:18675064
7 Segev D L, Gentry S E, Melancon J K, Montgomery R A. Characterization of waiting times in a simulation of kidney paired donation. Am J Transplant , 2005, 5(10): 2448-2455
doi: 10.1111/j.1600-6143.2005.01048.x pmid:16162194
8 Claas F H, Doxiadis I I. Management of the highly sensitized patient. Curr Opin Immunol , 2009, 21(5): 569-572
doi: 10.1016/j.coi.2009.07.010 pmid:19682882
9 Yoon H E, Hyoung B J, Hwang H S, Lee S Y, Jeon Y J, Song J C, Oh E J, Park S C, Choi B S, Moon I S, Kim Y S, Yang C W. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci , 2009, 24 (Suppl): S148-S155
doi: 10.3346/jkms.2009.24.S1.S148 pmid:19194545
10 Fourtounas C, Mouzaki A, Vlachojannis J G. Desensitization during renal transplantation. N Engl J Med , 2008; 359: 1731-1732
11 Jordan S C, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc , 2006, 117: 199-211 , discussion 211
12 Jordan S. IVIG vs. plasmapheresis for desensitization: which is better? Am J Transplant , 2006, 6(7): 1510-1511
doi: 10.1111/j.1600-6143.2006.01393.x pmid:16827849
13 Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant , 2002, 2(8): 758-760
doi: 10.1034/j.1600-6143.2002.20809.x pmid:12243496
14 Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schr?ppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg J S. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol , 2008, 3(4): 1160-1167
doi: 10.2215/CJN.05321107 pmid:18337549
15 Stegall M D, Gloor J, Winters J L, Moore S B, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant , 2006, 6(2): 346-351
doi: 10.1111/j.1600-6143.2005.01178.x pmid:16426319
16 Vo A A, Lukovsky M, Toyoda M, Wang J, Reinsmoen N L, Lai C H, Peng A, Villicana R, Jordan S C. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med , 2008, 359(3): 242-251
doi: 10.1056/NEJMoa0707894 pmid:18635429
17 Munoz A S, Rioveros A A, Cabanayan-Casasola C B, Danguilan R A, Ona E T. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc , 2008, 40(7): 2218-2221
doi: 10.1016/j.transproceed.2008.07.046 pmid:18790197
18 Buehrig C K, Lager D J, Stegall M D, Kreps M A, Kremers W K, Gloor J M, Schwab T R, Velosa J A, Fidler M E, Larson T S, Griffin M D. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int , 2003, 64(2): 665-673
doi: 10.1046/j.1523-1755.2003.00103.x pmid:12846764
No related articles found!
Full text